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 “For now we see through a glass, darkly; but 
then face to face.” 
 – 1 Corinthians 13 
 Th ese are exciting times for the distal 
convoluted tubule (DCT), or at least for 
those who study it. During the golden 
age of micropuncture, this short nephron 
segment was studied widely. Later, how-
ever, attention shift ed to other nephron 
segments, owing to ease of study and the 
belief that NaCl transport along the DCT 
is determined  ‘ in large part by delivered 
load, ’ with only  ‘ equivocal ’ evidence for 
regulatory modulation. 1 New molecular 
tools and techniques, coupled with ex-
citing insights into genetic hypertension 
and salt wasting, however, now identify 
the DCT as a key site for regulated NaCl 
transport. As with any fi eld that is mov-
ing rapidly, however, emerging results 
oft en raise confusing questions. Our un-
derstanding of DCT transport remains 
inchoate, but the paper by van der Lubbe 
and colleagues 2 (this issue) helps to bring 
some clarity. 
 During the past 15 years, evidence has 
accumulated that aldosterone increases 
sodium reabsorption along the DCT. 3 
More recently, arginine vasopressin (AVP) 
has also been shown to enhance sodium 
reabsorption along this segment. 4 
Aldosterone and AVP have long been 
known to stimulate Na transport along 
the cortical collecting duct, by acting on 
the epithelial Na channel (ENaC); AVP 
also increases water permeability of this 
segment (via aquaporin-2), where both 
the mineralocorticoid receptor (MR) and 
the vasopressin type 2 receptor (V2R) 
are expressed. Yet DCT cells also express 
MR 5 and V2R. 6 Th ese receptors prob ably 
mediate direct hormonal effects in 
the DCT, as aldosterone increases the 
acti vity 3 and abundance 7 of the thiazide-
sensitive Na-Cl cotransporter (NCC), as 
does AVP. 4,8,9 
 Th e dominant NaCl transport pathway 
of the DCT is NCC. To transport NaCl, 
NCC must move ( ‘ traffic ’ ) to, and be 
inserted into, the apical plasma mem-
brane; it is also phosphorylated along its 
amino-terminal cytoplasmic domain, 
enhancing activity ( Figure 1 ). WNKs are 
intracellular kinases that modulate NCC 
activity by altering both trafficking 
and phosphorylation. WNK4 reduces 
NCC movement to the apical membrane 10 
from sites where it is synthesized (the 
endoplasmic reticulum) and processed 
(the Golgi apparatus), at least in part, 
by targeting it to lysosomes, where it can 
be degraded; 11,12 the effects of WNK4 
may be modulated by angiotensin II 
(see below). In contrast, WNK3 increases 
NCC abundance and activity. 13 – 15 Th us, 
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 Figure 1  |  Simplified scheme of regulation of thiazide-sensitive Na-Cl cotransporter. The 
thiazide-sensitive Na-Cl cotransporter (NCC) is synthesized and then glycosylated (green forks) 
within the Golgi apparatus (not shown, for clarity). NCC then moves to and into the apical 
membrane, where it exists as a dimer. To be fully active, NCC undergoes phosphorylation along 
its amino-terminal cytoplasmic domain, mediated largely by SPAK, thereby permitting NaCl 
transport. Little is known about mechanisms of removal from the membrane. Arginine vasopressin 
(AVP), aldosterone (Aldo), and angiotensin II (Ang II) all stimulate NCC activity. Trafficking may be a 
rapid effect, modulated predominantly by AVP and Ang II. Phosphorylation may occur within the 
membrane and is enhanced by all three factors. 
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some WNKs are predominantly inhibi-
tory, whereas others are predominantly 
stimulatory, at least with respect to NCC. 
Little is known about how NCC is removed 
from the apical membrane, although the 
process does not appear to involve clath-
rin-mediated endocytosis. 12,16 
 As noted above, NCC is also activated 
by phosphorylation ( Figure 1 ). Phospho-
rylation activates NCC without changing 
its membrane abundance, at least when it 
is expressed heterologously in  Xenopus 
oocytes. 17 Th e major kinase that phos-
phorylates and activates NCC appears to 
be SPAK. 18,19 SPAK, which is expressed 
along the distal nephron, 20 can itself be 
phosphorylated and activated by WNK 
kinases, so that WNK, SPAK, and NCC 
constitute a signaling pathway. 21 Never-
theless, although kinase domains of the 
several WNKs are homologous, all WNKs 
do not appear to have the same eff ects on 
NCC. As noted above, WNK4 appears to 
act as an inhibitor of NCC, 10,22 at least 
under some conditions, 23 whereas WNK1 
phosphorylates SPAK to activate NCC. 19 
In HeLa cells, WNK1, but not WNK4, 
activated SPAK and caused a large shift  
in electrophoretic mobility; 24 thus, details 
of how WNK kinases modulate NCC 
remain confusing. 
 Angiotensin II is another component of 
the renin – angiotensin – aldosterone sys-
tem that stimulates Na transport along the 
DCT. 25 This effect is also likely to be 
direct, owing to the presence of angio-
tensin II type 1 (AT 1 ) receptors along the 
DCT. 26 Genetic deletion of AT 1a receptors 
reduces the abundance of NCC, 27 and 
infusion of angiotensin II for 8 days 
increases the abundance and phosphor-
ylation of NCC; 28 thus, angiotensin II and 
aldosterone appear to have similar eff ects 
on NCC activity. Gamba and colleagues 
reported that angiotensin II relieved the 
inhibitory eff ect of WNK4 on NCC, in a 
SPAK-dependent manner. 23 
 Angiotensin II increases NCC activity, 
in part, by increasing the abundance of 
NCC at the apical plasma membrane. Th is 
effect occurs rapidly, with short-term 
angiotensin II infusions increasing the 
ratio of apical to subapical NCC. 29 In cul-
tured mpkDCT cells, angiotensin II also 
increases SPAK and NCC phosphoryla-
tion, suggesting that acute exposure to 
angiotensin II also activates the trans-
porter allosterically. 28 Longer-term eff ects, 
induced by dietary NaCl restriction 30 or 
angiotensin II infusions, 28 also stimulate 
the activity of NCC and increase its abun-
dance and its phosphorylation; in these 
situations, however, the eff ects may be 
direct, from AT 1 -receptor activation, or 
indirect, via aldosterone stimulation. 
 Talati and colleagues concluded, on 
the basis of inhibitor studies, that long-
term eff ects of angiotensin II on NCC 
are mediated by aldosterone 28 and sug-
gested therefore that aldosterone is the 
predominant NCC regulatory factor. Th e 
paper by van der Lubbe and colleagues 2 
(this issue) shows clearly that angi-
otensin II itself increases NCC abun-
dance and phosphorylation, even during 
chronic exposure; the authors used the 
definitive approach of performing 
adrenalectomy, and then infusing hor-
mones chronically, to fi x adrenal steroid 
concentrations. The results are clear: 
angiotensin II increases NCC abundance 
and phosphorylation even when serum 
aldosterone levels are fi xed. Several addi-
tional points, derived from their data, 
however, deserve emphasis. 
 First,  Figure 2 , based on the data of van 
der Lubbe, 2 shows that aldosterone, but 
not angiotensin II, substantially increased 
the abundance of the   -subunit of ENaC 
(  ENaC). Th is pattern of hormonal eff ect 
on ENaC contrasts with eff ects on NCC, 
in which both angiotensin II and aldo-
sterone increase NCC abundance and 
phosphorylation. Th ese results help to 
explain how aldosterone, a single hor-
mone, can generate either NaCl retention 
or Na / K exchange, depending on the stim-
ulatory signal (an eff ect termed the  ‘ aldos-
terone paradox ’ 31 ). Th us, when aldosterone 
secretion is stimulated by angiotensin II 
(such as occurs when the extracellular 
fl uid volume is depleted), Na reabsorption 
will be stimulated along much of the neph-
ron (including the proximal and distal 
tubule, by angiotensin II, and the distal 
tubule and collecting duct, by aldoster-
one). Th ese eff ects will restore extracellu-
lar fl uid volume both because proximal 
segments reabsorb NaCl, and because Na 
delivery to the distal, K secretory sites will 
be limited. In contrast, when aldosterone 
secretion is stimulated by hyperkalemia, 
in the absence of changes in angiotensin 
II, Na reabsorption will only be stimulated 
distally, favoring the exchange of Na for K. 
Although other mechanisms are likely to 
be involved, the patterns of angiotensin II 
and aldosterone eff ect on Na transport 
along the nephron certainly refl ect physio-
logically adaptive processes. 
 Second, while NCC stimulation by 
either angiotensin II or aldosterone 
is associated with increases in SPAK 
abundance and SPAK phosphorylation, 
when animals received higher doses of 
angiotensin II, NCC appeared to be 
stimulated, even though SPAK (and phos-
phorylated SPAK) were at baseline levels; 
even though this eff ect did not quite reach 
statistical significance, it raises the 
possibility that other kinases can 
activate NCC. 
0
2
1
3
4
5
Aldo Ang II Ang II high
Fo
ld
 in
cr
ea
se
, v
s 
co
nt
ro
l
53P NCC
SPAK
Alpha ENaC
 Figure 2  |  The effects of aldosterone, angiotensin II, and pressor-dose angiotensin II on 
abundance of   ENaC, SPAK, and phosphorylated NCC. Note that all three interventions increase 
phosphorylated NCC, whereas aldosterone increases the abundance of the   -subunit of the 
epithelial Na channel (  ENaC) mimimally (Ang II) or not at all (Ang II high). Please see text for more 
details. Aldo, aldosterone; Ang II, angiotensin II; Ang II high, pressor-dose angiotensin II. (Based on 
the data of van der Lubbe  et al. 2 ) 
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 Finally, although comparisons of pro-
tein abundance do not necessarily refl ect 
changes in transporter activity, the ability 
of aldosterone to increase NCC abun-
dance is quite impressive, in comparison 
with its ability to increase ENaC abun-
dance. Many, if not most, introductory 
texts for medical and graduate students 
describe eff ects of aldosterone on ENaC 
but omit eff ects on NCC. 32 Th e accumu-
lating data suggest that it is time to break 
old paradigms, and include NCC as a cru-
cial aldosterone-regulated transport pro-
tein, when introducing students to the 
eff ects of adrenal steroids on the kidney. 
 Lest the current data be seen as clearing 
all confusion, several questions remain. 
As noted above, two groups 8,9 have shown 
that AVP increases traffi  cking and phos-
phorylation of NCC. In the study by van 
der Lubbe and colleagues, 2 the abundance 
of aquaporin-2 was increased by both 
aldosterone and angiotensin II infusion. 
Th is suggests either that these peptides 
stimulated AVP secretion or that angi-
otensin II activated V2R directly; there is 
some evidence in support of the second 
model. 33 From a physiological standpoint, 
of course, the striking similarity of eff ects 
of aldosterone and AVP on distal trans-
porters is hard to reconcile with eff ects on 
whole-animal balance. Aldosterone and 
AVP both stimulate ENaC  and NCC. Yet 
hyperaldosteronism typically presents 
with hypertension, owing to sodium chlo-
ride retention, while the syndrome of 
inappropriate antidiuretic hormone secre-
tion presents with hyponatremia, owing 
to effects on aquaporin-2, but without 
NaCl retention. Th is suggests either that 
the potency of stimulatory eff ects on Na 
transport, or the escape mechanisms that 
supervene, are diff erent, or that other fac-
tors come into play. One possible factor is 
V1a receptors; most studies of AVP 
actions use the V2-receptor-specifi c ago-
nist desmopressin (dDAVP). V1a recep-
tors, a second target of the native hormone 
AVP, can increase natriuresis. 34 
 Finally, the roles played by WNK 
kinases in modulating or mediating eff ects 
of angiotensin II and / or aldosterone 
remain intriguing but are not fully eluci-
dated. In view of the phenotype that 
results when WNK kinases are mutated, 
familial hyperkalemic hypertension 
(pseudohypoaldosteronism type II or 
Gordon syndrome), it seems clear that 
these kinases help to determine whether 
aldosterone is primarily kaliuretic or NaCl 
retentive. Yet changes in WNK4 were not 
observed in the experiments reported by 
van der Lubbe and colleagues, 2 and data 
concerning WNK1 or WNK3 are not 
reported. WNK kinases may play a crucial 
role in determining NCC membrane 
abundance and states of phosphorylation, 
but the roles of the individual players, and 
their integration, remain poorly under-
stood. Further, it seems likely that eff ects 
of WNK kinases, or at least WNK4, are 
modulated by circulating (or local) levels 
of angiotensin II, 23 as noted above. Much 
remains to be learned about the interac-
tions between WNKs, SPAK, NCC, and 
the rennin-angiotensin-aldosterone sys-
tem. Yet the possibility that small-mole-
cule WNK modulators might provide 
novel ways to  ‘ turn down ’ the distal neph-
ron means that this pathway is an attrac-
tive target for drug development. 
 DISCLOSURE 
 The author declared no competing interests. 
 REFERENCES 
 1 .  Koeppen  BM ,  Stanton  BA .  Sodium chloride 
transport: distal nephron .  In: Seldin DW, 
Giebisch G (eds).  The Kidney: Physiology and 
Pathophysiology .  2nd edn.  Raven Press: New York , 
 1992 ,  pp  2003 – 2040 . 
 2 .  van der Lubbe  N ,  Lim  CH ,  Fenton  RA  et al. 
 Angiotensin II induces phosphorylation of the 
thiazide-sensitive sodium chloride cotransporter 
independent of aldosterone .  Kidney Int  2011 ;  
 79 :  66 – 76 . 
 3 .  Velazquez  H ,  Bartiss  A ,  Bernstein  P  et al.  Adrenal 
steroids stimulate thiazide-sensitive NaCl 
transport by rat renal distal tubules .  Am J Physiol 
 1996 ;  270 :  F211 – F219 . 
 4 .  Ecelbarger  CA ,  Kim  G - H ,  Terris  J  et al.  Vasopressin-
mediated regulation of epithelial sodium channel 
abundance in rat kidney .  Am J Physiol Renal Physiol 
 2000 ;  279 :  F46 – F53 . 
 5 .  Bostanjoglo  M ,  Reeves  WB ,  Reilly  RF  et al. 
 11Beta-hydroxysteroid dehydrogenase, 
mineralocorticoid receptor, and thiazide-
sensitive Na-Cl cotransporter expression by 
distal tubules .  J Am Soc Nephrol  1998 ; 
 9 :  1347 – 1358 . 
 6 .  Mutig  K ,  Paliege  A ,  Kahl  T  et al.  Vasopressin V2 
receptor expression along rat, mouse, and human 
renal epithelia with focus on TAL .  Am J Physiol 
 2007 ;  293 :  F1166 – F1177 . 
 7 .  Kim  GH ,  Masilamani  S ,  Turner  R  et al.  The thiazide-
sensitive Na-Cl cotransporter is an aldosterone-
induced protein .  Proc Natl Acad Sci USA  1998 ;  95 : 
 14552 – 14557 . 
 8 .  Pedersen  NB ,  Hofmeister  MV ,  Rosenbaek  LL  
et al.  Vasopressin induces phosphorylation of the 
thiazide-sensitive sodium chloride cotransporter 
in the distal convoluted tubule .  Kidney Int  2010 ; 
 78 :  160 – 169 . 
 9 .  Mutig  K ,  Saritas  T ,  Uchida  S  et al.  Short-term 
stimulation of the thiazide-sensitive Na + -
Cl  –  cotransporter by vasopressin involves 
phosphorylation and membrane translocation . 
 Am J Physiol  2010 ;  298 :  F502 – F509 . 
 10 .  Yang  CL ,  Angell  J ,  Mitchell  R  et al.  WNK kinases 
regulate thiazide-sensitive Na-Cl cotransport .  
J Clin Invest  2003 ;  111 :  1039 – 1045 . 
 11 .  Subramanya  AR ,  Liu  J ,  Ellison  DH  et al.  WNK4 
diverts the thiazide-sensitive NaCl cotransporter 
to the lysosome and stimulates AP-3 interaction .  
J Biol Chem  2009 ;  284 :  18471 – 18480 . 
 12 .  Cai  H ,  Cebotaru  V ,  Wang  YH  et al.  WNK4 kinase 
regulates surface expression of the human sodium 
chloride cotransporter in mammalian cells .  Kidney 
Int  2006 ;  69 :  2162 – 2170 . 
 13 .  Glover  M ,  Zuber  AM ,  O ’ Shaughnessy  KM .  Renal 
and brain isoforms of WNK3 have opposite effects 
on NCCT expression .  J Am Soc Nephrol  2009 ;  20 : 
 1314 – 1322 . 
 14 .  Yang  CL ,  Zhu  X ,  Ellison  DH .  The thiazide-sensitive 
Na-Cl cotransporter is regulated by a WNK kinase 
signaling complex .  J Clin Invest  2007 ;  117 : 
 3403 – 3411 . 
 15 .  Rinehart  J ,  Kahle  KT ,  de Los Heros  P  et al.  WNK3 
kinase is a positive regulator of NKCC2 and NCC, 
renal cation-Cl   −   cotransporters required for 
normal blood pressure homeostasis .  Proc Natl 
Acad Sci USA  2005 ;  102 :  16777 – 16782 . 
 16 .  Golbang  AP ,  Cope  G ,  Hamad  A  et al.  Regulation 
of the expression of the Na/Cl cotransporter 
(NCCT) by WNK4 and WNK1: evidence that 
accelerated dynamin-dependent endocytosis 
is not involved .  Am J Physiol Renal Physiol  2006 ; 
 291 :  F1369 – F1376 . 
 17 .  Pacheco-Alvarez  D ,  Cristobal  PS ,  Meade  P  et al.  
The Na + : Cl  –  cotransporter is activated and 
phosphorylated at the amino-terminal domain 
upon intracellular chloride depletion .  J Biol Chem 
 2006 ;  281 :  28755 – 28763 . 
 18 .  Moriguchi  T ,  Urushiyama  S ,  Hisamoto  N  et al. 
 WNK1 regulates phosphorylation of cation-
chloride-coupled cotransporters via the STE20-
related kinases, SPAK and OSR1 .  J Biol Chem  2005 ; 
 280 :  42685 – 42693 . 
 19 .  Richardson  C ,  Rafiqi  FH ,  Karlsson  HK  et al. 
 Activation of the thiazide-sensitive 
Na + -Cl - cotransporter by the WNK-regulated 
kinases SPAK and OSR1 .  J Cell Sci  2008 ;  121 : 
 675 – 684 . 
 20 .  Reiche  J ,  Theilig  F ,  Rafiqi  FH  et al.  SORLA/SORL1 
functionally interacts with SPAK to control renal 
activation of Na + -K + -Cl  –  cotransporter 2 .  Mol Cell 
Biol  2010 ;  30 :  3027 – 3037 . 
 21 .  Richardson  C ,  Alessi  DR .  The regulation of salt 
transport and blood pressure by the WNK-SPAK/
OSR1 signalling pathway .  J Cell Sci  2008 ;  121 : 
 3293 – 3304 . 
 22 .  Wilson  FH ,  Kahle  KT ,  Sabath  E  et al.  Molecular 
pathogenesis of inherited hypertension with 
hyperkalemia: the Na-Cl cotransporter is inhibited 
by wild-type but not mutant WNK4 .  Proc Natl Acad 
Sci USA  2003 ;  100 :  680 – 684 . 
 23 .  San-Cristobal  P ,  Pacheco-Alvarez  D ,  Richardson  C 
 et al.  Angiotensin II signaling increases activity of 
the renal Na-Cl cotransporter through a WNK4-
SPAK-dependent pathway .  Proc Natl Acad Sci USA 
 2009 ;  106 :  4384 – 4389 . 
 24 .  Anselmo  AN ,  Earnest  S ,  Chen  W  et al.  WNK1 and 
OSR1 regulate the Na + , K + , 2Cl  –  cotransporter 
in HeLa cells .  Proc Natl Acad Sci USA  2006 ;  103 : 
 10883 – 10888 . 
 25 .  Wang  T ,  Giebisch  G .  Effects of angiotensin II on 
electrolyte transport in the early and late distal 
commentar y
8   Kidney International (2011) 79 
tubule in rat kidney .  Am J Physiol Renal Physiol 
 1996 ;  271 :  F143 – F149 . 
 26 .  Mujais  SK ,  Kauffman  S ,  Katz  AI .  Angiotensin II 
binding sites in individual segments of the rat 
nephron .  J Clin Invest  1986 ;  77 :  315 – 318 . 
 27 .  Brooks  HL ,  Allred  AJ ,  Beutler  KT  et al.  Targeted proteo-
mic profiling of renal Na(+) transporter and channel 
abundances in angiotensin II type 1a receptor 
knockout mice .  Hypertension  2002 ;  39 :  470 – 473 . 
 28 .  Talati  G ,  Ohta  A ,  Rai  T  et al.  Effect of angiotensin II on 
the WNK-OSR1/SPAK-NCC phosphorylation cascade 
in cultured mpkDCT cells and  in vivo mouse kidney . 
 Biochem Biophys Res Commun  2010 ;  393 :  844 – 848 . 
 29 .  Sandberg  MB ,  Riquier  AD ,  Pihakaski-Maunsbach 
 K  et al.  ANG II provokes acute trafficking of distal 
tubule Na + -Cl  –  cotransporter to apical membrane . 
 Am J Physiol  2007 ;  293 :  F662 – F669 . 
 30 .  Ellison  DH ,  Velazquez  H ,  Wright  FS .  Adaptation of 
the distal convoluted tubule of the rat. Structural 
and functional effects of dietary salt intake and 
chronic diuretic infusion .  J Clin Invest  1989 ;  83 : 
 113 – 126 . 
 31 .  Halperin  ML ,  Kamel  KS .  Dynamic interactions 
between integrative physiology and molecular 
medicine: the key to understand the mechanism 
of action of aldosterone in the kidney .  Can J Physiol 
Pharmacol  2000 ;  78 :  587 – 594 . 
 32 .  Briggs  JP ,  Kriz  W ,  Schnermann  JB .  Overview of 
kidney function and structure .  In: Greenberg A 
(ed).  Primer on Kidney Diseases .  5th edn.  Saunders: 
Philadelphia ,  2009 ,  pp  2 – 18 . 
 33 .  Jensen  AM ,  Bae  EH ,  Fenton  RA  et al.  Angiotensin II 
regulates V2 receptor and pAQP2 during ureteral 
obstruction .  Am J Physiol  2009 ;  296 :  F127 – F134 . 
 34 .  Perucca  J ,  Bichet  DG ,  Bardoux  P  et al.  Sodium 
excretion in response to vasopressin and selective 
vasopressin receptor antagonists .  J Am Soc 
Nephrol  2008 ;  19 :  1721 – 1731 . 
see original article on page 99
 Kidney function for the non-
nephrologist: an emerging tool 
for predicting mortality risk 
 Stein I.  Hallan 1 
 Estimated glomerular filtration rate (eGFR) and albuminuria are among 
the most important cardiovascular risk factors, but the optimal cutoff for 
predicting mortality may not yet have been agreed upon. Foley  et al. 
analyzed data from the population-based NHANES III study with 
classification tree methodology. They found that an eGFR of 94  ml / min 
per 1.73  m 2 and an albumin – creatinine ratio of 9  mg / g were the optimal 
cutoff values, that is, more  ‘ normal ’ values than are used to define 
chronic kidney disease. 
 Kidney International (2011)  79, 8 – 10.  doi: 10.1038/ki.2010.362 
 Cardiovascular disease has been a major 
public-health problem for more than 50 
years in the developed world. Enormous 
research eff orts have been undertaken to 
understand cardiovascular diseases, and 
great progress has been made in both pre-
vention and treatment. During the past 20 
years, we have experienced a tremendous 
decline in cardiovascular mortality among 
middle-aged people, and substantial 
improvements in treatment have also been 
achieved in the elderly. 1 
 Discovering major risk factors for car-
diovascular diseases and organizing these 
into risk prediction scores have been 
important in this progress. In the INTER-
HEART study, nine risk factors accounted 
for 90 % of the population attributable 
risk for incident myocardial infarctions. 2 
However, this might be too optimistic, 
and, at least in clinical practice, we are 
not able to predict 90 % of all future car-
diovascular events. Th e  ‘ number needed 
to treat ’ to prevent one cardiovascular 
event is still oft en estimated to be around 
100. 3 Th is rather high number is proba-
bly due to both lack of treatment eff ec-
tiveness and suboptimal risk stratifi cation 
of the patients, and, especially in the eld-
erly, the latter could be a substantial 
problem. Both the Framingham risk 
equation and the Systematic Coronary 
Risk Evaluation (SCORE) equation were 
developed for subjects younger than 70 
years old. Likewise, the predictive value 
of major risk factors such as hyperten-
sion and dyslipidemia is reduced in the 
elderly. 4 Th e reasons for this  ‘ reversed 
epidemiology ’ are several, but survival 
bias is probably one of the most impor-
tant. To improve risk stratifi cation testing 
for subclinical atherosclerosis could be 
one possible way forward, especially in 
the elderly. Measurement of carotid 
intima – media thickness and measure-
ment of coronary calcifications with 
ultrasound and computed tomographic 
scanning, respectively, are techniques 
with high diagnostic accuracy but low 
availability. 5 Chronic kidney disease has 
been increasingly suggested as a potential 
 ‘ test ’ for cardiovascular risk prediction, 
as it has high diagnostic accuracy like the 
aforementioned methods, has no side 
eff ects, and is much cheaper. However, 
the optimal use of estimated glomerular 
fi ltration rate (eGFR) and urinary albu-
min excretion is not yet agreed upon. 
 Foley  et al. 6 (this issue) make an inter-
esting contribution to this topic. Using the 
large population-based Th ird National 
Health and Nutrition Examination Survey 
(NHANES III) cohort from the United 
States, they studied how well kidney func-
tion and other risk factors predicted mor-
tality risk, using classifi cation tree analysis. 
Th eir main fi nding is that, for optimal 
prediction of mortality risk, more  ‘ near-
normal ’ cutoff  values for kidney function 
should be used. Th e current 2002 Kidney 
Disease Outcomes Quality Initiative 
(KDOQI) uses an eGFR below 60  ml / min 
per 1.73  m 2 and an albumin – creatinine 
ratio above 30  mg / g for defi nition and risk 
classifi cation of chronic kidney disease 
and its outcomes. Cutoff s for mortality-
risk prediction could, however, be diff er-
ent, and Foley  et al. 6 suggest using an 
eGFR of 94  ml / min per 1.73  m 2 and 
an albumin – creatinine ratio of 9  mg / g as 
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